TP53 and prostate carcinoma: In prostate cancer, a strategy targeting both the hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy causes tumor regression in xenografts, leads to near-complete tumor suppression and remarkably prolongs the survival of a PTEN/P53-deficient mouse model (29).